Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Laszlo

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Blood|December 7, 2013
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AMLGeorge S Laszlo, Chelsea J Gudgeon, Kimberly H Harrington, et al.
Oncotarget|June 2, 2016
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaGeorge S Laszlo, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Leukemia|April 12, 2014
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemiaR B Walter, G S Laszlo, J M Lionberger, et al.
Leukemia & Lymphoma|February 25, 2014
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Rhonda E Ries, Chelsea J Gudgeon, et al.
Cancers|October 26, 2024
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell DisordersSheryl Y T Lim, Jenny Huo, George S Laszlo, et al.
Molecular Therapy. Oncology|September 3, 2024
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, et al.
Plos One|January 16, 2013
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinDavid B Rosen, Kimberly H Harrington, James A Cordeiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2015
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Cancers|January 10, 2026
DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute LeukemiaCamryn M Pettenger-Willey, George S Laszlo, Margery Gang, et al.
Leukemia|April 27, 2022
Development of [<sup>211</sup>At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood|December 7, 2013
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AMLGeorge S Laszlo, Chelsea J Gudgeon, Kimberly H Harrington, et al.
Oncotarget|June 2, 2016
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaGeorge S Laszlo, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Leukemia|April 12, 2014
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemiaR B Walter, G S Laszlo, J M Lionberger, et al.
Leukemia & Lymphoma|February 25, 2014
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Rhonda E Ries, Chelsea J Gudgeon, et al.
Cancers|October 26, 2024
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell DisordersSheryl Y T Lim, Jenny Huo, George S Laszlo, et al.
Molecular Therapy. Oncology|September 3, 2024
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, et al.
Plos One|January 16, 2013
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinDavid B Rosen, Kimberly H Harrington, James A Cordeiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2015
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Cancers|January 10, 2026
DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute LeukemiaCamryn M Pettenger-Willey, George S Laszlo, Margery Gang, et al.
Leukemia|April 27, 2022
Development of [<sup>211</sup>At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Pageof 4